Could a biosimilar eye injection offer a new way to treat diabetic macular edema?

NCT ID NCT04674800

Completed Disease control Sponsor: Mylan Pharmaceuticals Inc Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing MYL-1701P, a proposed biosimilar to the existing eye medication Eylea, in people with diabetic macular edema who have already completed an earlier study with the same drug. The goal is to see if continued treatment with MYL-1701P is safe and effective over a longer period. Participants will receive three injections of the drug, given eight weeks apart, and will be monitored for side effects and changes in vision and retinal thickness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MYL-1701P, a proposed biosimilar to Eylea (aflibercept), given as eye injections
What this could lead to: If successful, this could support MYL-1701P as a safe and effective alternative to Eylea, potentially offering a more affordable treatment option for diabetic macular edema.
What could go wrong: This is an extension study with a small number of participants, so results may not be conclusive. As with any eye injection, there are risks of eye infection, inflammation, or increased eye pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA

Contacts and locations

Locations

Mylan Investigative Site

Visakhapatnam, Andhra Pradesh, 530 040, India
Mylan Investigative Site

Ahmedabad, Gujarat, 380015, India
Mylan Investigative Site

Bangalore, Karnataka, 560094, India
Mylan Investigative Site

Bengaluru, Karnataka, 560037, India
Mylan Investigative Site

Mumbai, Maharashtra, 400050, India
Mylan Investigative Site

Chandigarh, Punjab, 160012, India
Mylan Investigative Site

Noida, Uttar Pradesh, 201301, India
Mylan Investigative site

Hyderabad, Andhra Pradesh, 500034, India
Mylan Investigative site

Ahmedabad, Gujarat, 380016, India
Mylan Investigative site

Bangalore, Karnataka, 560 010, India
Mylan Investigative site

New Delhi, New Delhi, 110029, India
Mylan Investigative site

Bhubaneswar, Odisha, 751024, India
Mylan Investigative site

Jaipur, Rajasthan, 302015, India
Mylan Investigative site

Madurai, Tamil Nadu, 625 020, India
Mylan Investigative site

Tirunelveli, Tamil Nadu, 627002, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.